Life Sciences Regulation in Finland: Overview

Thomson Reuters Practical Law Life Sciences Global Guide 2023

A Q&A guide to life sciences regulation in Finland.

This Q&A provides a high-level overview of key practical issues, including life sciences clinical trials, manufacturing, marketing, abridged procedure, pharmacovigilance, data privacy, packaging and labelling, biological medicines, medical devices, health care IT, combination products, borderlines, and natural health products.

Read the Finland chapter we contributed: Life Sciences Regulation in Finland: Overview

Read also: Life Sciences Commercialisation in Finland: Overview

More by the same author

Implementing the Data Act without Clashing with the GDPR?

The Data Act will largely apply as of 12 September 2025, imposing new obligations and rights in relation to personal and non-personal data in the context of, e.g., connected products and related services. As rules governing data expand, it is increasingly important to map what data sets are processed by an organisation and how they are managed in the upcoming regulatory framework. For data sets including personal data (which is often the case!), it is vital to align the implementation of the Data Act with existing GDPR compliance.

New Legislation on Environmental Marketing: Sustainable Businesses Benefit from Ban on Greenwashing

New EU legislation on green claims will bring opportunities to sustainable businesses, although ensuring compliance with the new rules will require preparatory efforts from companies. As stricter and more detailed rules will apply to environmental claims and marketing, to prevent so-called greenwashing, companies with a genuinely sustainable product range will benefit from the new framework. Prohibition of greenwashing brings advantages to both consumers and businesses – and naturally to the environment.

The EU’s Pharmaceutical Legislation Reform

The European Union’s imminent pharmaceutical legislation reform aims to modernise its regulatory framework, focusing on improving patient access to medicines, fostering innovation, and minimising environmental impact. This strategic overhaul, set against a backdrop of industry challenges and evolving IP rights, underscores the EU’s commitment to balancing innovation with accessibility and sustainability in healthcare.

Latest insights

Are Finnish Lawyers the Happiest in the World?

Article / 4 Apr 2024
Reading time 2 minutes

Implementing the Data Act without Clashing with the GDPR?

Article / 4 Apr 2024